Discover a groundbreaking webinar delving into weight loss in metabolic disease and how imaging can provide insights in this field. Weight loss is a very popular topic amidst the recent unprecedented effects of newly developed pharmacotherapies. However, it is becoming increasingly apparent that we need to better understand what is happening underneath the lost kilos.
Where is the weight loss really coming from? What effects does weight loss have in the context of other organs and disease states? And how can these insights be used to advance drug development?
The underlying biology of metabolic diseases is complex, there are many different pathways and mechanisms involved. In addition to discussing biology, the featured speakers will dig deeper into learnings from bariatric surgery and previous obesity and diabetes clinical trials.
Finally, they will cover how imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), can help to answer the burning questions surrounding weight loss in drug development.
Join this webinar to learn about weight loss, the underlying biology, drug development and how imaging can be used to further our understanding of metabolic disease.
Lena Carlsson Ekander, Professor, Department of Molecular and Clinical Medicine, University of Gothenburg
Lena Carlsson Ekander’s research is focused on the long-term effects of bariatric surgery and elucidating the genes and molecular mechanisms involved in the development of obesity and associated metabolic diseases. Since 2005 she has led the Swedish Obese Subjects (SOS) study, the only large prospective controlled trial in the world with very long-term (> 30 years) follow up of the effects of bariatric surgery in patients with obesity. Many of the results from the SOS study have been published in high ranked journals, including NEJM and JAMA.
Björn Carlsson, Executive Medical Director, Early Clinical Development, AstraZeneca
Björn Carlsson has an MD and PhD from Gothenburg University, Sweden. He has over 20 years’ experience from drug development in metabolic diseases including obesity, diabetes, NASH, and dyslipidemia. He has clinical experience treating obesity and an extensive research experience in obesity and co-morbidities with over 150 peer-reviewed publications with an H-index over 50.
Lars Johansson, Chief Scientific Officer, Antaros Medical
Lars Johansson has a PhD in translational imaging from Uppsala University in Sweden. He has over 180 published peer-reviewed papers and several book chapters on imaging in drug development. Lars has 35 years of experience in clinical imaging in the cardiometabolic and renal disease areas and about 25 years of experience within the pharma industry. Prior to his current position, he was a Senior Principal Scientist at AstraZeneca R&D. In his current role as Chief Scientific Officer at Antaros Medical he is involved in designing clinical studies using imaging endpoints with Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET). The prototyping of new imaging methods also includes the development of PET tracers for fibrosis, inflammation and immunology/immuno-oncology.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Drug developers
- Clinical Researchers
- Clinical development
- Clinical operations
- Clinical Project Leaders
- Procurement leads
- Medical/Scientific leads
What You Will Learn
Attendees will gain insights into:
- The underlying biology and mechanisms of weight loss and metabolic disease
- A need for biomarkers to help researchers better understand weight loss and the pharmacotherapies being developed
- Imaging as a solution, a biomarker for understanding what is happening underneath the lost kilos
Antaros Medical is pioneering imaging methodologies, using magnetic resonance imaging (MRI) and positron emission tomography (PET) to design and deliver clinical studies for decision making and differentiation in drug development. Specialised in cardiorenal, metabolic, and fibrotic diseases, Antaros Medical develops and tailors imaging solutions to provide valuable insights throughout the drug development process. The company has a global network of collaborators and customers, including both large and small drug development companies, and is a partner in several European research consortia, such as the Innovative Medicine Initiative (IMI) and COST. Antaros Medical has its headquarters & CoreLab in Sweden, with a subsidiary in US.